New pill for Hard-to-Treat cancers enters first human tests
NCT ID NCT07244835
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitored by their doctors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your body shape predict radiation accuracy?
- New drug naderin may help patients fight infections during cancer and TB therapy
- New study aims to uncover why some women have worse sexual side effects from radiation
- New injection YKYY031 enters human testing for Hard-to-Treat cancers
- New robot arm takes on cancer surgery – first safety check begins
- New combo therapy aims to shrink kidney tumors in Late-Stage trial